Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by DekaBank Deutsche Girozentrale

Key Points

• DekaBank Deutsche Girozentrale reduced its stake in Regeneron Pharmaceuticals by 4.5% during the second quarter, owning approximately $110 million worth of shares post-sale.
• Regeneron reported earnings of $12.89 per share for the last quarter, significantly surpassing analyst estimates of $8.43, leading to a revenue of $3.68 billion.
• The company has a dividend yield of 0.6% following a quarterly dividend payment of $0.88, with a low payout ratio of 8.87%.

DekaBank Deutsche Girozentrale trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.5% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 211,207 shares of the biopharmaceutical company's stock after selling 9,969 shares during the quarter. DekaBank Deutsche Girozentrale owned approximately 0.20% of Regeneron Pharmaceuticals worth $110,009,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of Regeneron Pharmaceuticals by 344.4% in the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares during the last quarter. Activest Wealth Management raised its holdings in shares of Regeneron Pharmaceuticals by 110.5% in the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $27,000. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $27,000. Finally, Colonial Trust Advisors purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $32,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $576.77 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $991.23. The business's 50-day simple moving average is $575.25 and its 200-day simple moving average is $562.14. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a market capitalization of $61.13 billion, a P/E ratio of 14.54, a P/E/G ratio of 1.80 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the prior year, the business earned $11.56 earnings per share. The company's revenue was up 3.6% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.87%.

Analyst Ratings Changes

REGN has been the subject of a number of recent analyst reports. Guggenheim lifted their price objective on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating for the company in a research report on Friday, October 10th. Citigroup lifted their price objective on Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a "buy" rating in a research report on Monday, October 13th. Sanford C. Bernstein lifted their price objective on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an "outperform" rating in a research report on Wednesday, August 27th. Finally, BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a research report on Monday, August 4th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $817.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.